| _version_ |
1826206006606036992
|
| collection |
MIT
|
| description |
Immune checkpoint blockade (ICB) results in durable disease control in a subset of patients with advanced renal cell carcinoma (RCC), but mechanisms driving resistance are poorly understood. We characterize the single-cell transcriptomes of cancer and immune cells from metastatic RCC patients before or after ICB exposure. In responders, subsets of cytotoxic T cells express higher levels of co-inhibitory receptors and effector molecules. Macrophages from treated biopsies shift toward pro-inflammatory states in response to an interferon-rich microenvironment but also upregulate immunosuppressive markers. In cancer cells, we identify bifurcation into two subpopulations differing in angiogenic signaling and upregulation of immunosuppressive programs after ICB. Expression signatures for cancer cell subpopulations and immune evasion are associated with PBRM1 mutation and survival in primary and ICB-treated advanced RCC. Our findings demonstrate that ICB remodels the RCC microenvironment and modifies the interplay between cancer and immune cell populations critical for understanding response and resistance to ICB.
|
| first_indexed |
2024-09-23T13:22:30Z
|
| format |
Article
|
| id |
mit-1721.1/136118
|
| institution |
Massachusetts Institute of Technology
|
| language |
English
|
| last_indexed |
2024-09-23T13:22:30Z
|
| publishDate |
2021
|
| publisher |
Elsevier BV
|
| record_format |
dspace
|
| spelling |
mit-1721.1/1361182022-04-01T17:20:50Z Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma Immune checkpoint blockade (ICB) results in durable disease control in a subset of patients with advanced renal cell carcinoma (RCC), but mechanisms driving resistance are poorly understood. We characterize the single-cell transcriptomes of cancer and immune cells from metastatic RCC patients before or after ICB exposure. In responders, subsets of cytotoxic T cells express higher levels of co-inhibitory receptors and effector molecules. Macrophages from treated biopsies shift toward pro-inflammatory states in response to an interferon-rich microenvironment but also upregulate immunosuppressive markers. In cancer cells, we identify bifurcation into two subpopulations differing in angiogenic signaling and upregulation of immunosuppressive programs after ICB. Expression signatures for cancer cell subpopulations and immune evasion are associated with PBRM1 mutation and survival in primary and ICB-treated advanced RCC. Our findings demonstrate that ICB remodels the RCC microenvironment and modifies the interplay between cancer and immune cell populations critical for understanding response and resistance to ICB. 2021-10-27T20:30:53Z 2021-10-27T20:30:53Z 2021 2021-07-23T16:36:50Z Article http://purl.org/eprint/type/JournalArticle https://hdl.handle.net/1721.1/136118 en 10.1016/j.ccell.2021.02.015 Cancer Cell Creative Commons Attribution-NonCommercial-NoDerivs License http://creativecommons.org/licenses/by-nc-nd/4.0/ application/pdf Elsevier BV Elsevier
|
| spellingShingle |
Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma
|
| title |
Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma
|
| title_full |
Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma
|
| title_fullStr |
Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma
|
| title_full_unstemmed |
Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma
|
| title_short |
Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma
|
| title_sort |
tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma
|
| url |
https://hdl.handle.net/1721.1/136118
|